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ABSTRACT
Introduction: Increasing evidence suggests obesity
has its origins prior to birth. There is clear correlation
between maternal obesity, high birthweight and
offspring risk of obesity in later life. It is also clear that
women who are obese during pregnancy are at greater
risk of adverse outcomes, including gestational
diabetes and stillbirth. The mechanism(s) by which
obesity causes these problems is unknown, although
hyperglycaemia and insulin resistance are strongly
implicated. We present a protocol for a study to test
the hypothesis that metformin will improve insulin
sensitivity in obese pregnant women, thereby reducing
the incidence of high birthweight babies and other
pregnancy complications.
Methods and analysis: The Efficacy of Metformin in
Pregnant Obese Women, a Randomised controlled
(EMPOWaR) trial is a double-masked randomised
placebo-controlled trial to determine whether
metformin given to obese (body mass index >30 kg/
m2) pregnant women from 16 weeks’ gestation until
delivery reduces the incidence of high birthweight
babies. A secondary aim is to test the mechanism(s) of
any effect. Obese women with a singleton pregnancy
and normal glucose tolerance will be recruited prior to
16 weeks’ gestation and prescribed study medication,
metformin or placebo, to be taken until delivery.
Further study visits will occur at 28 and 36 weeks’
gestation for glucose tolerance testing and to record
anthropometric measurements. Birth weight and other
measurements will be recorded at time of delivery.
Anthropometry of mother and baby will be performed
at 3 months postdelivery. As of January 2014, 449
women had been randomised across the UK.
Ethics and dissemination: The study will be
conducted in accordance with the principles of Good
Clinical Practice. A favourable ethical opinion was
obtained from Scotland A Research Ethics Committee,
reference number 10/MRE00/12. Results will be
disseminated at conferences and published in peer-
reviewed journals.
Trial registration number: ISRCTN51279843.
BACKGROUND, INCLUDING RATIONALE AND
ANY PREVIOUS SYSTEMATIC REVIEWS
Rates of obesity, as deﬁned by a body mass
index (BMI) greater than 30 kg/m2, are
rising alarmingly in the UK and throughout
the world. Around 27% of adults in Scotland
are now obese and 32% of Scottish children
have a weight outwith a healthy range for
their age.1 Obesity rates in England2 and the
USA3 are similar. The increase in average
BMI during pregnancy over the past 20 years
has been well documented.4 Rates of mater-
nal obesity in women booking for antenatal
care in the UK are now around 20%. There
has also been a substantial increase in mean
birth weight and in the incidence of being
born large for gestational age over the past
few decades.5 The secular rise in maternal
weight at delivery appears to be the factor
most strongly correlated with the increase in
birth weight.5 6 Positive correlations have also
been shown between birth weight and both
maternal pregravid weight7–9 and weight gain
in pregnancy,10 with odds of high birth
weight some 2.4 times greater in morbidly
obese compared with lean women.11
This increase in mean birth weight is of
concern because it is linked to an increased
likelihood of child and adult obesity. A sys-
tematic review showed a positive correlation
between birth weight and obesity during
adulthood.12 The association between high
birth weight and later life obesity is also sup-
ported by two large epidemiological
studies13 14 both of which found obesity to
be a long-term correlate of high birth
weight. A subsequent prospective study
found that children who were large for
Strengths and limitations of this study
▪ This is the first multicenter, double-masked, ran-
domised controlled trial to examine the effect of
metformin in obese pregnant women without
diabetes.
▪ We will use a recognised surrogate (birthweight
centile) as a marker of future life risk of obesity
in the offspring.
▪ Follow-up of the offspring is limited to the early
postnatal phase.
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gestational age at birth and exposed to an intrauterine
environment of maternal obesity are also at increased
risk of developing metabolic syndrome.15 Our own
recent work suggests that offspring of obese pregnant
women are at increased risk of premature death in adult-
hood.16 Thus, the increase in rates of maternal obesity
are setting up a vicious cycle, leading to increased birth
weight and increased rates of child and adult obesity,
contributing to an epidemic of obesity which has
become one of the most signiﬁcant contributors to
global ill health.
Women who are obese during pregnancy are also
themselves at greater risk of a number of adverse out-
comes, including gestational diabetes,17 pre-eclampsia18
and stillbirth.19 20 The mechanism(s) by which maternal
obesity increases pregnancy and peripartum complica-
tions are unclear, but there are likely several candidate
mechanisms including hyperglycaemia and increased
insulin resistance.
Clearly an intervention is urgently required. Lifestyle
interventions (eg, diet and exercise) are a logical
approach and are currently being trialled, for example,
UK Pregnancies Better Eating and Activity Trial
(UPBEAT), Poston (ISRCTN89971375) although studies
hitherto have shown no evidence of beneﬁt.21–23 A
recent meta-analysis of dietary and lifestyle interven-
tions suggests dietary interventions may be of some
beneﬁt over physical activity or mixed interventions in
reducing maternal weight gain. However, there was no
effect on birth weight, the incidence of large for gesta-
tional age babies and clinically important adverse
outcomes.24
In this study, we test the hypothesis that the insulin-
sensitising agent metformin reduces birthweight centile
in the offspring of obese pregnant women. The princi-
pal action of metformin includes improvement of
insulin resistance in the liver and skeletal muscle, along
with improved endothelial function, increased periph-
eral uptake of glucose, improved lipid proﬁle, redistribu-
tion of fat from visceral to subcutaneous depots and
antioxidant effects,25 all of which are likely to contribute
to its clinical efﬁcacy in reducing adverse outcomes in
obese pregnant women.
Considerable evidence implicates insulin resistance or
hyperglycaemia as the mechanism by which maternal
obesity causes excessive neonatal birth weight. While
modest insulin resistance is physiological in pregnancy
and generates maternal glucose, free fatty acids and
amino acids as substrates for fetal growth, obese preg-
nant women are more insulin resistant than their lean
counterparts6 leading to a further ampliﬁcation of nutri-
ent availability with consequent excessive fetal growth.
There is a strong correlation between insulin resistance
in late gestation and both birth weight and fat-free mass
at birth.26 The Hyperglycaemia and Adverse Pregnancy
Outcomes (HAPO) trial27 conﬁrms that there is a linear
relationship between hyperglycaemia and birth weight,
even at glucose levels not usually considered abnormal
during pregnancy. The Australian Carbohydrate
Intolerance Study in Pregnant Women (ACHOIS)28 con-
ﬁrms that treating hyperglycaemia can substantially
reduce both the incidence of large for gestational age
babies and other perinatal complications. Thus, metfor-
min, by reducing insulin resistance, could have a major
impact in reducing excess birth weight in obese preg-
nant women.
This study is timely because of emerging evidence
about the safety and efﬁcacy of metformin. It is a
licensed ﬁrst-line therapy for the treatment of type 2 dia-
betes and is endorsed by National Institute for Health
and Care Excellence (NICE) as a treatment for gesta-
tional diabetes.29
There are few previous studies testing the effects of
metformin in pregnant women in the absence of dia-
betes. A small randomised study of 40 pregnant women
with a history of polycystic ovarian syndrome (PCOS), a
condition often accompanied by insulin resistance,
showed that metformin reduced predeﬁned pregnancy
complications from 32% in the placebo group (n=22) to
0% in the metformin group (n=18; p=0.01).30 However,
a larger study by the same group, which randomised 274
women with PCOS to either metformin or placebo
throughout pregnancy, showed no signiﬁcant differences
in the prevalence of preterm birth, pre-eclampsia and
gestational diabetes.31 There was also no difference in
birth weights of the babies in the two groups. However,
the mean BMI of the participants in these studies was
less than 30 kg/m2. In the Metformin in Gestational dia-
betes (MiG) study, which compared the effect of metfor-
min versus insulin in women with gestational diabetes,32
there were no differences in birth weight between the
offspring. However, weight gain in pregnancy, a known
additional driver of birth weight,7 was lower in the met-
formin group (difference of 1.6 kg, p<0.001). By 2 years
of age, offspring of the participants randomised to met-
formin had greater subcutaneous fat, but overall body
fat was the same as in children whose mothers were
treated with insulin alone, suggesting that the ‘metfor-
min offspring’ have smaller deposits of visceral, metabol-
ically active fat.33 Further follow-up is required to
examine whether these ﬁndings persist into later life
and whether children exposed to metformin will be
more insulin sensitive.
Importantly, if metformin is to be effective in reducing
high birth weight in obese women, it should not
increase the proportion of babies with low birth weight.
The studies aforementioned, and another small study,
on women with a mean BMI less than 30 kg/m2 are
reassuring on this point.30 31 34
HYPOTHESIS
We hypothesise that metformin administered to obese
women during pregnancy will reduce birthweight centile
in their babies and consequently their future life risk of
obesity and metabolic syndrome.
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AIM
To determine if metformin administered to obese
women during pregnancy reduces birthweight centile in
their babies, using birth weight as a surrogate marker of
the future life risk of obesity and metabolic syndrome in
the offspring.
OBJECTIVES
Primary objective
To determine the efﬁcacy of metformin (up to 2500 mg
daily), given to obese pregnant women from between 12
and 16 weeks’ gestation until delivery, in reducing gesta-
tional age-adjusted and sex-adjusted birthweight centile
of the baby.
Secondary objectives
▸ To determine the pattern of association between insulin
resistance and adverse pregnancy outcomes, including
incidence of pregnancy-induced hypertension, pre-
eclampsia, caesarean section, postpartum haemorrhage,
maternal weight gain during pregnancy and incidence
of the baby’s admission to the neonatal unit.
▸ To determine the effect of metformin on maternal
body composition.
▸ To determine the effect of metformin on neonatal
body composition.
▸ To determine the effect of metformin on maternal
inﬂammatory and metabolic variables (measured at
28 and 36 weeks’ gestation) and on neonatal inﬂam-
matory variables (measured in cord blood at birth).
▸ To conﬁrm that metformin does not increase the rate
of babies with a low birthweight centile.
▸ To determine the efﬁcacy (as opposed to the effect-
iveness) of metformin when analysis is restricted to
those with pharmacological circulating levels of drug.
A series of nested substudies will also be performed with
the following objectives:
▸ To determine the effect of metformin on maternal
cortisol levels in obese pregnant women.
▸ To determine the effect of metformin in hepatic and
peripheral insulin sensitivity at 36 weeks’ gestation in
obese pregnant women.
▸ To determine the effect of metformin on
endothelium-dependent ﬂow-mediated dilatation in
obese pregnant women.
▸ To determine the effect of metformin on maternal
subcutaneous and visceral adipose tissue deposition
and hepatic and skeletal muscle ectopic fat depos-
ition during pregnancy.
▸ To determine the effect of metformin on fetal liver
volume and subcutaneous fat deposition.
▸ To determine the effect of metformin on myometrial
contractility and myometrial glycogen storage in
obese pregnant women.
▸ To determine the effect of metformin on placental
glucocorticoid receptor and 11 βHSD 1 and 2 mRNA
levels.
CENTRE(S)
Seventeen hospitals in the UK.
DESIGN
The design is a double-masked randomised placebo-
controlled trial, with embedded substudies to explore
mechanism of action of metformin, in a population of
∼400 obese pregnant women (ﬁgure 1).
INCLUSION AND EXCLUSION CRITERIA
Screening phase inclusion criteria
▸ Caucasian obese (BMI ≥30 kg/m2) pregnant women
between 12+0 and 16+0 weeks’ gestation;
▸ Age greater than or equal to 16 years;
▸ Signed informed consent form.
Screening phase exclusion criteria
▸ Non-Caucasian;
▸ BMI <30 kg/m2;
▸ Gestation >16+0 weeks;
▸ Pre-existing diabetes;
▸ Gestational diabetes in a previous pregnancy;
▸ Systemic disease at the time of trial entry, with the disease
either requiring regular medication or having required
treatment with systemic steroids in the past 3 months;
▸ Previous delivery of a baby <3rd centile by weight;
▸ Previous pregnancy complicated by pre-eclampsia
prompting delivery before 32 weeks’ gestation;
▸ Known sensitivity to metformin hydrochloride or any
of the excipients;
▸ Acute conditions at the time of trial entry with the
potential to alter renal function such as dehydration
sufﬁcient to require intravenous infusion, severe
infection, shock, intravascular administration of iodi-
nated contrast agents;
▸ Acute or chronic diseases which may cause tissue
hypoxia such as cardiac or respiratory failure, recent
myocardial infarction, hepatic insufﬁciency, acute
alcohol intoxication, alcoholism;
▸ Lactation;
▸ Multiple pregnancy.
Randomisation exclusion criteria following screening
▸ Gestational diabetes mellitus (GDM) in index preg-
nancy (diagnosed with 75 g oral glucose tolerance test
using WHO criteria, see table 1). Participants are also
excluded if glucose tolerance test is diagnostic of GDM
based on the criteria used in the recruiting centre.
▸ Known liver or renal failure or dysfunction at the
time of trial entry tested prior to randomisation
(deﬁned as variable above the reference range shown
in table 2).
Ineligible and non-recruited participants
No further information will be collected on women who
are ineligible solely because of abnormalities in glucose
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tolerance, liver or renal function, other than the
number of such women for inclusion in trial metrics.
Telephone or face-to-face interviews will be carried
out to explore the reasons for eligible women declining
to participate.
METHODS
We will recruit women attending maternity hospitals in
the UK. Women who fulﬁl all the potential eligibility cri-
teria and who express an interest in the study will be
provided with the participant information sheet and
given at least 24 h to consider participation. They will
then be asked to provide written informed consent.
Following consent, participants will have screening
blood tests including liver and renal function and a 75 g
oral glucose tolerance test, to determine eligibility for
randomisation. Participants will have demographics,
Figure 1 Flow chart of
participants in the trial.
Table 1 WHO diagnostic criteria for gestational diabetes
following 75 g oral glucose tolerance test
Time (hours) Blood glucose (mmol/L)
0 ≥7.0
2 ≥7.8
Table 2 Reference ranges for biochemical parameters
Variable Range
Urea 2.5–6.6 mmol/L
Creatinine <85 μmol/L
Sodium 135–145 mmol/L
Potassium 3.6–5.0 mmol/L
Bilirubin 3–16 μmol/L
ALT 10–60 IU/L
ALT, alanine transaminase.
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medical history, height, weight and anthropometry mea-
surements (waist, hips, mid-arm, mid-thigh circumfer-
ence; tricep, bicep and subscapular skinfolds) recorded
at this visit.
RANDOMISATION
Eligible participants will be randomly assigned to active
treatment with metformin or an identical looking
placebo. This will be documented in the patient’s paper
case record and/or computer ﬁle to show the woman’s
participation in the trial.
Participants will be randomised via a web portal con-
nected to a central randomisation facility based at the
trial data centre, the Edinburgh Clinical Trials Unit,
University of Edinburgh. Baseline eligibility data will be
required before randomisation. Participants will be ran-
domised in a 1:1 ratio to metformin or placebo.
Randomisation will be stratiﬁed by treatment centre and
BMI 30–39 vs >40 kg/m2.
CONCEALMENT OF ALLOCATION
Randomising participants to active or placebo tablets
will achieve concealment of allocation. Placebo tablets
will appear identical to active treatment, so that the par-
ticipant is masked to treatment allocation. The outcomes
will be measured by clinicians and investigators masked
to treatment allocation. Masking will not be broken until
after data entry is complete, the validity of the data is
checked, all queries resolved, the patient populations
agreed and the database locked. Any clinically indicated
emergency unmasking will be recorded prospectively.
INTERVENTION
Metformin tablets (or matched placebo) 500 mg admi-
nistered from as soon as practicable after the point of
randomisation (and certainly between 12 and 16 weeks’
gestation) until delivery of the baby. The dose regimen
is as follows: week 1, 500 mg once daily; week 2, 500 mg
twice a day; week 3, 500 mg three times a day; week 4,
500 mg morning and lunchtime and 1000 mg in the
evening; week 5 until delivery of the baby, 1000 mg in
the morning and evening and 500 mg at lunchtime. All
doses are taken with food and dose escalation should
continue to either the maximum tolerable dose or
2500 mg, whichever is higher.
Dose changes
The local investigator or participant may alter the treat-
ment regimen at his/her discretion, so long as the
maximum daily dose does not exceed 2500 mg. Changes
to the treatment dose will be recorded in the electronic
case report form (eCRF) as soon as practicable.
Other medications
Alcohol is prohibited due to the increased risk of lactic
acidosis. Iodinated contrast agents may increase the risk
of renal failure; hence, if they are required, metformin
should be discontinued for at least 48 h from immedi-
ately prior to contrast agent administration until after
renal function has been re-evaluated and found to be
normal. Clinicians prescribing glucocorticoids (systemic
and local routes), β2-adrenoreceptor agonists and ACE
inhibitors should be aware that they might amplify or
diminish the hypoglycaemic effect of metformin.
STUDY ASSESSMENTS
Following randomisation, study assessments for glucose
tolerance testing and other tests will occur as detailed in
table 3.
Maternal anthropometric measurements recorded at
baseline, 36 weeks’ gestation and 3 months postpartum,
will include waist; hip; upper arm and thigh circumfer-
ence and bicep, tricep and subscapular skinfold thick-
ness. Neonatal anthropometric measurements recorded
within 72 h of birth and at 3 months of age will include
head circumference, and tricep and subscapular skin-
fold thickness. Length and weight will be recorded in
order to calculate ponderal index.
Fasting maternal blood samples obtained at baseline,
28 and 36 weeks’ gestation will be stored for future ana-
lysis of inﬂammatory and metabolic indices, including
(but not limited to) insulin, C reactive protein (CRP),
interleukin (IL)-6, leptin, plasminogen activator inhibi-
tor (PAI)1/PAI2 ratio, cortisol, lipids and non-esteriﬁed
fatty acids. Cord blood obtained at the time of delivery
will also be taken for measurement of glucose and
stored for future measurement of the inﬂammatory and
metabolic indices listed previously.
Table 3 also documents the timing of the nested sub-
studies in which a subgroup of participants will partici-
pate. A summary of these is given below.
Saliva samples
Diurnal cortisol levels will be measured in saliva samples
collected at baseline, 28 and 36 weeks’ gestation. Saliva
will be collected in salivettes at bedtime and on waking.
Samples will be stored at −80°C. Cortisol will be mea-
sured by ELISA.
Body composition
Maternal fat mass will be measured using air displace-
ment plethysmography (BOD POD, http://www.
lifemeasurement.com) at baseline, 36 weeks’ gestation
and 3 months postpartum. Neonatal fat mass will be
measured using the same technique (PEA POD, http://
www.lifemeasurement.com) within 72 h of birth and at
3 months of age.
Hyperinsulinaemic euglycaemic clamp
A subgroup of women will undergo a hyperinsulinaemic
euglycaemic clamp study at 36 weeks’ gestation to char-
acterise the relative effects of metformin on hepatic and
peripheral insulin sensitivity.
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Table 3 Summary of study visits
Visit number 1 2 3 4 5 6 7 8 9
Gestation 10–16 weeks 10–16 weeks 12–16 weeks 18–20 weeks 28 Weeks 36 Weeks Term
Labour/
delivery/
neonatal
3 months
postnatally
Screening Consent Randomisation
Study visit
(could be by
telephone)
Study
visit
Study
visit
Study visit
(could be by
telephone) Study visit Study visit
Review inclusion and
exclusion criteria
X
Patient information leaflet X
Consent form X
Demographics X
Medical history X
Height and weight X X
Maternal anthropometry X X X
Bloods for liver function/
renal function/full lipid
profile/CRP
X X
75 g OGTT (sampling at
baseline and 2 hours)
X X X
Stored sample for
inflammatory and
metabolic indices
X X X
Randomisation X
Study drug dispensed X X
Unused study drug/
packaging returned
X
Review SAEs X X X X X
Complete side effects
questionnaire on eCRF
X X X X X
Review and record
pregnancy complications
X X X X X
Saliva samples for
cortisol measurements
X X X
Bodpod measurements X (OR VISIT 3) X (OR VISIT 2) X X
Hyperinsulinaemic
euglycaemic clamp
X
FMD X X
MR scan X X
Labour/delivery
information including birth
weight, mode of delivery,
EBL
X
Continued
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Flow-mediated dilatation
Endothelium-dependent ﬂow-mediated dilatation will be
measured in a subgroup of participants at baseline and
again at 36 weeks’ gestation. Change in diameter of the
brachial artery following a ﬂow stimulus created by arter-
ial occlusion will be measured using continuous two-
dimensional grayscale ultrasound imaging.
MRI and spectroscopy
A subgroup of participants will be scanned at 28 and
36 weeks’ gestation using a Verio 3 Tesla MRI system.
T1-weighted acquisitions will be used to measure mater-
nal subcutaneous and visceral fat; fetal liver volume; and
fetal subcutaneous fat. Images will be analysed using the
software program SliceOmatic. This program uses
knowledge-based image processing to label pixels as fat
or non-fat components and the adipose tissue mass
derived using a mathematical model. Hepatic and skel-
etal muscle lipid content will be measured using
1H-magnetic resonance spectroscopy.
Myometrial biopsies
A biopsy of the lower segment myometrium will be
obtained from consenting participants who are delivered
by caesarean section. The biopsies will be divided, with
one portion placed in physiological saline for contractil-
ity studies and the other snap frozen for glycogen
storage measurements.
PARTICIPANT COMPLIANCE
Compliance will be recorded in a treatment diary and by
counting of unused tablets. Additionally, gas chromatog-
raphy mass spectrometry will be used to analyse metfor-
min levels in blood samples from participants in the
third trimester.
OUTCOMES
Primary outcome
Z-score corresponding to the gestational age-adjusted
and sex-adjusted birthweight centiles of the baby.
Secondary outcomes
▸ Maternal insulin resistance at 36 weeks’ gestation,
which will be correlated with adverse pregnancy
outcomes.
▸ Maternal anthropometry and body composition at 16
and 36 weeks’ gestation and 3 months postpartum.
▸ Baby anthropometry and body composition at birth
and 3 months of age.
▸ Maternal inﬂammatory markers, lipid and fatty acid
indices prior to starting treatment and again at 28
and 36 weeks’ gestation including CRP, IL-6, leptin,
lipid proﬁle, non-esteriﬁed fatty acids, polyunsatur-
ated fatty acids and PAI1/PAI2 ratio.
▸ Neonatal CRP, glucose, insulin and other inﬂamma-
tory and metabolic indices as previously described
(measured in cord blood at birth).
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▸ Incidence of low birthweight centile.
▸ Gas chromatography mass spectrometry measure-
ment of metformin in maternal plasma to determine
adherence.
Secondary outcomes from nested substudies;
▸ Maternal salivary cortisol levels at baseline, 28 and
36 weeks’ gestation.
▸ Hepatic and peripheral insulin sensitivity at 36 weeks’
gestation as measured by the hyperinsulinaemic
euglycaemic clamp technique.
▸ Maternal brachial artery endothelium ﬂow-mediated
dilatation measured at 16 and 36 weeks’ gestation.
▸ Maternal subcutaneous and visceral adipose tissue
deposition and hepatic and skeletal muscle ectopic
fat deposition assessed using MRI and magnetic res-
onance spectroscopy.
▸ Fetal liver volume and fetal subcutaneous fat depos-
ition assessed using MRI.
▸ In vivo measurements of myometrial contractility on
myometrial biopsies obtained at the time of caesarean
section.
▸ Placental glucocorticoid receptor and 11 βHSD 1
(β hydroxysteroid dehydrogenase 1) and 2 mRNA levels.
SIDE EFFECTS AND ADVERSE EVENTS REPORTING
Participants are instructed to contact their investigator at
any time after consenting to randomisation if any symp-
toms develop. In the case of any events, the investigator
will initiate the appropriate treatment according to their
medical judgement. Participants with adverse events
(AEs) present at their last visit will be followed up until
resolution of the event. All AEs and serious AEs (SAEs)
that occur after randomisation will be recorded in detail
in the participant’s medical notes. SAEs occurring in the
mother or baby from the time a participant is rando-
mised until 30 days after stopping taking study treatment
or until 28 days after delivery (whichever is later) will be
reported to the co-sponsors using the trial documenta-
tion. The standard deﬁnition of a SAE will be used.35
For the purposes of this study the following events will
not be considered SAEs: miscarriage; preterm labour;
preterm prelabour spontaneous rupture of membranes;
preterm delivery in the maternal interest; preterm deliv-
ery in the fetal interest; hospitalisation for
pregnancy-induced hypertension; hospitalisation for
maternal discomfort; hospitalisation for rest; hospitalisa-
tion for observation or monitoring for which the woman
is admitted for a period of less than 12 h; delivery com-
plications such as caesarean section or postpartum
haemorrhage; admission of the baby to the neonatal
unit for a period of up to 14 days.
STATISTICAL ANALYSIS PLAN, INCLUDING SAMPLE SIZE
AND POWER CALCULATIONS
Birthweight centiles
In a previous study, the mean (SD) birth weight in a
cohort of obese women (mean BMI 34 kg/m2) was 4.0
(0.6) kg.36 We hypothesise that metformin will reduce
mean birth weight by 0.2 kg, corresponding to a reduc-
tion in birthweight centile of 0.33 SD. We believe that
this reduction is clinically relevant, but is a relatively con-
servative estimate of likely reduction in birthweight
centile induced by metformin, given that mean birth
weight in the study described above in a parallel non-
obese cohort was 3.4 kg. A sample size of 143 in each
group will have 80% power to detect a difference in
mean birthweight centile of 0.33 SD (the difference
between a placebo mean of 4.0 kg and a metformin
mean of 3.8 kg) at the 5% signiﬁcance level (2-sided)
using a two group t test; a sample size of 163 in each
group will give the study 85% power to detect these dif-
ferences. In practice, we will recruit a larger sample size
to allow loss to follow-up.
Type of analysis and statistical tests
The primary analysis will be by intention to treat. Mean
birthweight centile will be compared between the two
groups using a two-sample t test, but with the analysis
stratiﬁed for the same factors as the randomisation.
Correlations within the metformin and placebo groups
will be used to determine associations between insulin
resistance and adverse pregnancy outcomes.
INTERIM ANALYSIS AND STOPPING RULES
No formal interim analysis is planned (other than those
requested by the Data Monitoring Committee (DMC)).
COMMITTEE OVERSIGHTS
There is an independent Trial Steering Committee and
an independent Data Monitoring Committee to oversee
the safety of the participants in the trial.
DISCUSSION
Despite recognition that obesity represents a major
public health problem, and that adult obesity may have
its origins before birth, there is a lack of any effective
intervention for obese pregnant women to improve
pregnancy outcomes and reduce the future life risk of
obesity for their offspring. In light of convincing evi-
dence that the harmful effects of obesity during preg-
nancy are related to hyperglycaemia or insulin
resistance, treatment during pregnancy with metformin
is an exciting potential therapy. The Efﬁcacy of
Metformin in Pregnant Obese Women, a Randomised
controlled (EMPOWaR) trial is designed to establish
whether improving insulin sensitivity in pregnancy miti-
gates some of the adverse risk associated with obesity,
with the primary aim of examining the effect on the
birth weight of the baby, using birth weight as a surro-
gate marker of future life risk of obesity. A series of
embedded mechanistic studies will help us to
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understand more about the mechanism of effect of
metformin.
If our study ﬁnds metformin to be beneﬁcial in reducing
excess birth weight in obese pregnant women, it presents a
potential future therapy where none currently exist. Clearly
further large studies will be required to corroborate our
ﬁndings. To our knowledge, there is currently only one
other randomised double-masked placebo-controlled trial
in progress which aims to recruit 850 women with a BMI
>35 kg/m2 and is due to complete in September 2014
(Shehata, http://clinicaltrials.gov/show/NCT01273584).
As for any drug trial in pregnant women, safety is
clearly a priority. Metformin has been used for decades
in pregnant women with no evidence of any teratogenic
effects. We do not expect any adverse effects from terato-
genicity in our study population. There is no evidence
from previous studies that metformin increases the inci-
dence of babies with a low birthweight centile and we
hope to conﬁrm this with our data. Longer term
follow-up studies of the offspring will be needed to
assess the beneﬁts or adverse effects in later life of ante-
natal exposure to metformin.
Finally, metformin is an inexpensive drug, costing
under £5 per month. Obesity and the associated mater-
nal and fetal complications are a huge ﬁnancial burden
on health services.37 If metformin were found to be
effective, its use could contribute to signiﬁcant ﬁnancial
savings for health services.
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